The FDA thinks German Merck could have a breakthrough in its hands with a new lung cancer drug that targets aggressive tumours with a mutation known as MET.
With Merck KGaA’s multiple sclerosis drug evobrutinib entering phase 3 trials, we spoke to the company’s Fernando Dangond and MS expert Dr Xavier Montalban to get their views on the biggest
Merck KGaA and Pfizer’s immunotherapy Bavencio (avelumab) has been approved by the FDA in combination with Pfizer’s Inlyta (axitinib) for the first-line treatment of
Germany’s Merck KGaA has announced new mid-stage data that it says support further studies into its BTK inhibitor drug evobrutinib in multiple sclerosis, which could provide patients with a
Merck KGaA is doubling down on AI through a new collaboration agreement with tech firm Iktos, using its generative modelling technology to speed up the discovery and design of promising new
